Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 63

recruiting
3 972
countries
28
conditions
2 103

1 088 trials match your criteria

Duchenne muscular dystrophy

Not recruiting

Study on Long-Term Safety and Effectiveness of Vamorolone in Boys with Duchenne Muscular Dystrophy Who Completed Previous Vamorolone Studies

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Vamorolone

Gastric cancer+1

Not recruiting

Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Colorectal cancer metastatic

Not recruiting

Study Comparing Sotorasib and Panitumumab with Other Drug Combinations for Patients with Metastatic Colorectal Cancer and KRAS p.G12C Mutation

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab

Bladder transitional cell carcinoma+2

Not recruiting

Study of Durvalumab and Tremelimumab for Patients with Advanced Unresectable Urothelial Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin

Hodgkin's disease

Not recruiting

Title: Comparing Brentuximab Vedotin plus ESHAP versus ESHAP alone in treating patients with relapsed or refractory classical Hodgkin's Lymphoma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin

Acute myeloid leukaemia (in remission)

Not recruiting

Study of Galinpepimut-S compared to standard therapy for patients with acute myeloid leukemia who achieved complete remission after second-line treatment

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine

Duchenne muscular dystrophy

Not recruiting

Study on Eteplirsen for Patients with Duchenne Muscular Dystrophy with Deletion Mutations Amenable to Exon 51 Skipping

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Eteplirsen

Obesity

Not recruiting

Study of Setmelanotide for Patients with Obesity Due to Specific Genetic Variants

Registered drug
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Setmelanotide

Hidradenitis

Not recruiting

Study of lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab

Head and neck cancer

Not recruiting

Study of NBTXR3 and Cetuximab with Radiotherapy for Elderly Patients with Advanced Head and Neck Cancer Not Eligible for Platinum Chemotherapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab

Systemic candida

Not recruiting

Study of Recombinant Interferon-Gamma 1b Combined with Standard Treatment for Patients with Candidemia: Safety and Effectiveness Evaluation

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Recombinant human interferon gamma 1B

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.